Great article, interesting points about the impact of claim scope on generic/bioequivalence considerations, and risks associated with creating a patent prosecution record that doesn't match information provided to the FDA.

It's a tricky time for Lykos to raise money from more conventional biotech investors. Not only did it receive a rejection from the FDA last summer, but it also received two major rejections from the US Patent and Trademark Office, which have gone largely unreported.

Psychedelic reform in the US? Delighted to collaborate with the UC Berkeley Center for the Science of Psychedelics #BCSP and @psychedelicalpha.bsky.social to launch a new interactive map to track the rapidly evolving landscape of psychedelic law and policy reform across the US Our aim is to… 1/2

SF frens—I hope you brave the pouring rain and join us, we’ll have hot drinks and the fire going:

Psychedelics and DeSci? If you're in SF and interested in either, please join us Friday night for a PsyDAO meet up: lu.ma/9nxavwlp